Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011242 · ClinicalTrials.gov registry record
DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 47
- Enrollment target
NCT03011242 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 47 participants.
The verdict
NCT03011242 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
The Investigators will examine if DC-STAMP can serve as an early marker of TNFi response in PsA. Identification of such a biomarker would permit rapid transition to a new agent, a major treatment advance. TNFi are the most effective therapies in PsA, however, methotrexate is frequently initiated early in the disease course based on its significantly lower cost. Unfortunately, the efficacy of MTX has not been supported in clinical trials and up to 40% of patients do not respond to TNFi therapy. Moreover, valid biomarkers to predict MTX or TNFi responses are currently unavailable. This study may also provide the first data on the comparative efficacy of MTX and TNFi using clinical, Ultrasound (US) and biomarker outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-01-11 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03011242
The ClinicalTrials.gov registry entry for NCT03011242 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03011242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03011242 about?
NCT03011242 is a clinical study titled "DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA". The Investigators will examine if DC-STAMP can serve as an early marker of TNFi response in PsA. Identification of such a biomarker would permit rapid transition to a new agent, a major treatment advance. TNFi are the most effective therapies in PsA, however, methotrexate is frequently initiated ear...
What is the current status of trial NCT03011242?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-01-11. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT03011242?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.